• Regorafenib, RRM2, and Melanoma Progression

  2026-10-03

  A 2024 iScience study identifies RRM2 reduction and ERK/E2F3 signaling as important components of Regorafenib activity in melanoma models. The findings extend the compound’s established multikinase context by linking its antitumor phenotype to a DNA-replication-associated regulator, while remaining preclinical and model dependent.

• Regorafenib Suppresses Melanoma Through RRM2

  2026-10-02

  The 2024 iScience study identifies RRM2 as a functional downstream mediator of Regorafenib activity in melanoma and links this response to ERK/E2F3 signaling. Its combination of phenotypic assays, RNA sequencing, inhibition and rescue experiments, and tumor models provides a mechanistic framework for studying BAY 73-4506 beyond its established multikinase profile.

• EGFP mRNA m1Ψ as a Translation-Lifecycle Probe

  2026-10-01

  EGFP mRNA m1Ψ can do more than report delivery: it can help dissect how RNA architecture, cellular location, and mRNA decay shape protein expression. This guide connects the R1003 reporter to new insights from therapeutic mRNA metabolism while defining practical assay limits.

• Lysis Buffer for Better Mouse Genotyping

  2026-10-01

  This guide explains how a lysis buffer supports reliable mouse genotyping and genomic DNA release from mouse tail samples. It also develops a quality-control framework linking model verification with, but carefully separating it from, colorectal cancer transcriptomic research.

• Rifampin as a Causal Tool in Bacterial RNA Biology

  2026-09-30

  Rifampin is more than a rifamycin antibiotic: it is a precise perturbation for connecting RNA-polymerase inhibition with bacterial phenotype. This guide presents an assay-centered framework for resistance research, transcriptional regulation, synthetic biology, and rigorous interpretation of transcription-inhibition data.

• 3D Electrophysiology of Cardiac Organoids

  2026-09-30

  The reference study introduces shape-adaptive shell microelectrode arrays that wrap cardiac organoids and record electrical activity across three-dimensional tissue. By combining extracellular mapping, calcium imaging, and pharmacological challenges, the platform extends cardiac electrophysiology research beyond the planar limitations of conventional microelectrode arrays.

• TQB3720 Drives Ferroptosis Through the AR/GPX4 Axis

  2026-09-29

  The reference study identifies TQB3720 as a second-generation androgen receptor antagonist that suppresses prostate cancer by coupling AR inhibition to GPX4-dependent ferroptosis. Its integrated cell, organoid, animal, biochemical, and transcriptional experiments connect disrupted AR/SP1 signaling with lipid peroxidation and tumor growth inhibition.

• Nuclear PI3P and DNA Mismatch Repair: Vps34 Study

  2026-09-29

  The reference study identifies nuclear phosphatidylinositol-3-phosphate (PI3P) as a lipid regulator of DNA mismatch repair (MMR), extending Beclin-1/Vps34 biology beyond autophagy and endosomal trafficking. Its findings connect nuclear PI3P depletion with defective MutS complex assembly, microsatellite instability, impaired DNA-damage signaling, and altered 6-thioguanine responses.

• Regorafenib Reduces RRM2 in Melanoma

  2026-09-28

  A 2024 iScience study identifies RRM2 as a mechanistically important downstream target of Regorafenib in melanoma. Through cell assays, RNA sequencing, RRM2 perturbation, rescue experiments, signaling analysis, and in vivo studies, the authors connect reduced RRM2 with ERK/E2F3-dependent suppression of melanoma progression.

• From Lipid Rafts to Low-Abundance Protein Signals

  2026-09-28

  A translational perspective on how cancer-associated fibroblast-derived fatty acids may reshape oral cancer signaling—and why sensitive, well-controlled immunoblotting matters when validating the biology.

• Calpain Inhibitor II, ALLM for Protease Research

  2026-09-27

  Use Calpain Inhibitor II, ALLM to probe cysteine-protease biology—from apoptosis assays in leukemia and lymphoma to exploratory studies of calpain-dependent FAK turnover. Its broad target profile makes careful controls and orthogonal readouts essential, especially when extending findings to TNBC.

• PFHxS Hepatotoxicity and PPAR Signaling in Zebrafish

  2026-09-26

  This study combines transcriptomic screening with liver pathology, biochemical measurements, and targeted intervention to show that environmentally relevant PFHxS exposure can impair liver development and function in larval zebrafish. Antagonist treatment and PPAR knockdown alleviated several hepatic effects, strengthening the case for PPAR signaling as a contributor while leaving the responsible receptor subtype and human relevance open for further testing.

• SGC-CBP30: Practical Guide to Cell Assays

  2026-09-25

  A scenario-driven guide to using SGC-CBP30 (SKU A4491), a CREBBP/EP300 bromodomain inhibitor, in cell viability and transcriptional studies. It covers assay design, handling, interpretation, and how to evaluate the evidence when extending epigenetics research into lung adenocarcinoma models.

• Camostat Mesilate: From Protease Probe to Pathway Logic

  2026-09-25

  Camostat Mesilate is a trypsin-like protease inhibitor used to investigate epithelial ion-channel regulation and fibrotic signaling. This article explains how to interpret its effects as pathway evidence, and how a distinct structure-guided antiviral study sharpens decisions about choosing the right type of molecular perturbation.

• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-09-24

  A 2025 study found that anagliptin relaxed phenylephrine-contracted rabbit aortic rings, with inhibitor experiments implicating voltage-dependent potassium channels and the SERCA pump. The findings identify a vascular action worth investigating alongside DPP-4 inhibition, while leaving the molecular targets and relevance to intact organisms unresolved.

7976 records 1/532 page Next 12345 下5页 Last page